#United States #New York #Class Action #Baxter International #Novum LVP

Gross Law Firm Initiates Class Action for Baxter International Shareholders

The Gross Law Firm has officially filed a securities class action in New York for shareholders of Baxter International, Inc. (NYSE: BAX) as of November 6, 2025. This significant step has been prompted by serious concerns about the safety of Baxter's products, specifically their newly released device, the Novum LVP. Shareholders who purchased BAX stock from February 23, 2022, to July 30, 2025, are urged to register for possible participation as lead plaintiffs in this case.

Overview of the Allegations

The legal filing points to a range of allegations against Baxter International, asserting that the company misled investors regarding the safety and efficacy of the Novum LVP. Key claims include the following:

• - Systemic Defects in the Novum LVP: Reports indicate that the Novum LVP suffered from significant performance issues, such as underinfusion and overinfusion, ultimately leading to catastrophic malfunctions. These defects have put patients at risk, raising concerns of serious complications or even death.

• - Knowledge of Failures: Documents presented in the complaint suggest that Baxter was aware of multiple incidents involving device malfunctions, including injuries and fatalities related to the product defects. Despite this knowledge, the company allegedly failed to provide adequate alerts that could mitigate the risks to patients.

• - Inadequate Remedial Measures: The complaint expresses concerns regarding Baxter’s attempts to address the device flaws, suggesting that the company’s responses were insufficient and failed to rectify the underlying design flaws that continue to endanger patients.

• - Risk of Product Withdrawal: As these issues gained attention, there was an increased risk that healthcare providers would be compelled to withdraw existing Novum LVPs from service, which would severely impact Baxter's sales and market position.

Importance of Prompt Action

The deadline for shareholders to register for the class action and express interest in potential lead plaintiff roles is set for December 15, 2025. Shareholders who want to partake in any recovery process must be proactive in registering their claims. Importantly, registering does not obligate them to take a position as lead plaintiffs, offering a pathway for involvement without direct responsibility in the case's management.

Baxter International has seen significant scrutiny over these allegations, especially given the potential for severe regulatory consequences and the impact on investor trust. As the situation develops, it remains vital for shareholders to stay updated through monitoring resources offered via registration with the Gross Law Firm.

Next Steps for Affected Shareholders

Once registered, shareholders will gain access to real-time updates regarding the class action proceedings. This will include Details on the company's movements, court proceedings, and any changes pertaining to the lawsuits. Interested parties are encouraged to visit Gross Law Firm's registration page for more information.

Why Choose the Gross Law Firm?

With a reputation as a nationally recognized class action firm, the Gross Law Firm emphasizes its commitment to advocating for the rights of investors. The firm aims to hold companies accountable for misleading statements and to protect investor interests by pursuing compensation for losses incurred.

For further assistance, shareholders can explore the contact details of the Gross Law Firm:

• - Address: 15 West 38th Street, 12th Floor, New York, NY 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

This unfolding situation presents a crucial juncture for Baxter’s shareholders, as the ramifications of the allegations could significantly impact both their investments and the broader market perception of Baxter International's corporate governance and product safety protocols. The Gross Law Firm is determined to ensure that these issues are addressed and that affected investors receive the protections they deserve.